COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD ZincZn
HC Q study #37
Source   PDF   Share   Tweet
See all 155 studies
5/16
Inconc.
Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Macias et al., medRxiv, 10.1101/2020.05.16.20104141 (Preprint)
Similar incidence of Coronavirus Disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxych loroquine therapy
Very small retrospective study of rheumatic disease patients, sample size is too small for statistical significance (HC Q 0.5-4.0%, no-HC Q 0.4-2.7%). Confirmed cases were 1 HC Q and 2 no-HC Q, confirmed+likely cases were 1 HC Q and 3 no-HC Q. 1 HC Q and 2 no-HC Q patients were admitted to hospital. We do not think a conclusion can be drawn based on these sample sizes.
There are very significant differences between the groups, for example 30% of the HC Q group have SLE vs. 2.5% of the no-HC Q group. SLE patients have a 5.7 times relative risk of pneumonia according to [1], whereas the relative risk with glucocorticoids and TNF-α inhibitors is significantly lower [2]. Two more recent studies with rheumatic disease/autoimmune condition patients provide higher confidence.
hospitalization, ↓25.5%, p=1.00
COVID-19 case, ↑49.0%, p=0.53
Source   PDF   Share   Tweet
See all 155 studies
Please send us corrections, updates, or comments.
Submit